SLKovid Seroprevalence of SARS-CoV-2 in employees of a clinic with COVID-centre (COVID-19)

SARS-CoV-2 antibody test in connection with a short questionnaire (especially regarding field of work, prior tests, prior illness and prior symptoms).

Study Overview

Study nameSLKovid Seroprevalence of SARS-CoV-2 in employees of a clinic with COVID-centre (COVID-19)
ProjectSLKovid
Sources of Monetary or Material SupportPrivate sponsorship, Institutional budget
Region(s)Germany
Location(s)Heilbronn
Primary outcomeSerum analyses of antibodies against SARS-CoV-2 at 0 (if positive, additionalley at 3, 6 and 12 months) plus questionnaire
Secondary outcome[Characterisation of the immune answer to SARS-CoV-2 Comparison of several commercially available CE-certified test Systems Confirmation by neutralisation test Analysis of infection rate by exposition and field of work Evaluation of risk factors and prevention factors]
Study population N3000
Total population in the area125960
Principal InvestigatorUwe Martens , SLK Kliniken , dilyana.vladimirova@slk-kliniken.de
Team members
  • Uwe Martens, Principal Investigator, SLK Kliniken
  • Dilyana Vladimirova, Scientific Officer, SLK Kliniken
Period2020-07-01 till 2020-12-31
Study start2020-07-01
First results expected2020-12-31

Study metadata

{
   "abbreviation": "SLKovid",
   "draft": false,
   "iscjklanguage": false,
   "lastmod": "2021-02-25T11:00:18+01:00",
   "recruitment": {
     "country": [
       "Germany"
     ],
     "group": "general population",
     "location": [
       {
         "latitude": 49.1427,
         "longitude": 9.2109,
         "place_name": "Heilbronn"
       }
     ],
     "type": "monocenter diagnostic trial"
   },
   "study_dates": {
     "sample_end": "2020-12-31",
     "sample_start": "2020-07-01",
     "study_first_results": "2020-12-31",
     "study_start": "2020-07-01"
   },
   "study_info": {
     "funding_sources": "Private sponsorship, Institutional budget",
     "primary_outcomes": "Serum analyses of antibodies against SARS-CoV-2 at 0 (if positive, additionalley at 3, 6 and 12 months) plus questionnaire",
     "secondary_outcomes": [
       "Characterisation of the immune answer to SARS-CoV-2",
       "Comparison of several commercially available CE-certified test Systems",
       "Confirmation by neutralisation test",
       "Analysis of infection rate by exposition and field of work",
       "Evaluation of risk factors and prevention factors"
     ]
   },
   "study_numbers": {
     "population": 125960,
     "study_population": 3000
   },
   "study_pi": {
     "email": "dilyana.vladimirova@slk-kliniken.de",
     "institution": "SLK Kliniken",
     "name": "Uwe Martens",
     "role": "Professor"
   },
   "team": [
     {
       "institution": "SLK Kliniken",
       "name": "Uwe Martens",
       "position": "Head of Department for Haematology, Oncology \u0026 Palliative care",
       "role": "Principal Investigator",
       "title": "Prof. Dr. med."
     },
     {
       "institution": "SLK Kliniken",
       "name": "Dilyana  Vladimirova",
       "position": "Lead of Scientific Queries",
       "role": "Scientific Officer",
       "title": "PhD"
     }
   ],
   "title": "SLKovid Seroprevalence of SARS-CoV-2 in employees of a clinic with COVID-centre (COVID-19)"
 }